Abstract
Immune activation and chronic inflammation are recognized as major component of HIV disease even in patients with undetectable viral load. We evaluated the effect of atorvastatin on CD38 activation in such patients, in a case-control study (133 cases - 266 controls). At week 48, CD38 activation was significantly lower in cases vs. controls, with no difference in high-sensitivity C-reactive protein (hsCRP) and CD4. These results suggest that atorvastatin reduces the level of immune activation in patients with undetectable viral load.
MeSH terms
-
ADP-ribosyl Cyclase 1 / genetics
-
ADP-ribosyl Cyclase 1 / metabolism*
-
Atorvastatin
-
CD4-Positive T-Lymphocytes / immunology*
-
Down-Regulation
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / immunology*
-
Heptanoic Acids / pharmacology*
-
Humans
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology*
-
Male
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / metabolism*
-
Pyrroles / pharmacology*
-
Viral Load
Substances
-
Heptanoic Acids
-
Membrane Glycoproteins
-
Pyrroles
-
Atorvastatin
-
CD38 protein, human
-
ADP-ribosyl Cyclase 1